Document Detail

Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study.
MedLine Citation:
PMID:  8281719     Owner:  NLM     Status:  MEDLINE    
Hemodialysis patients are frequently affected by peptic disease, and in many cases they have high serum levels of gastrin. The aim of this study was to evaluate the effects of omeprazole, an inhibitor of gastric parietal cells hydrogen pump, on peptic disease and gastric secretion of 16 selected dialysis patients. H2-receptors blocking drugs or gastric acidity buffers were withdrawn for 2 weeks, then omeprazole was administered for 4 weeks at a daily dosage of 20 mg. Before and after the omeprazole therapy, registration of subjective peptic symptoms, baseline serum gastrin dosage and endoscopy of upper digestive tract were performed. Before starting omeprazole, the serum gastrin value was 515 +/- 180 pg/l, all the patients complained of peptic symptoms, and endoscopy showed: 8 cases of duodenal ulcer, 3 cases of pyloric ulcer and 5 cases of antral erosive gastritis. At the end of the omeprazole treatment period, a slight but statistically not significant increase of serum gastrin level (537 +/- 198 pg/l) was observed. Twelve patients reported the total disappearance of symptoms of peptic disease, 3 patients a partial reduction, and 1 patient had no improvement. Control endoscopy showed the healing (white scar) of all the ulcers, and the disappearance of all the erosive lesions. In conclusion, our results show that a 20 mg/day omeprazole short-term therapy can be given safely to uremic patients undergoing hemodialysis and is effective for a quick healing of active peptic lesions.
N E Montemurro; A Di Maggio; A Loperfido; M Franceschi; A Scatizzi
Related Documents :
2662389 - Sucralfate in the treatment of reflux esophagitis in adults: an update.
1543819 - Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duode...
2093019 - Australian clinical trials of omeprazole in the management of reflux oesophagitis.
6103209 - Somatostatin and cimetidine in peptic-ulcer haemorrhage. a randomised controlled trial.
3473639 - Treatment of xerostomia in patients with primary sjögren's syndrome with sulfarlem.
8085509 - A randomized controlled trial of a high support hospital discharge team for elderly peo...
21369739 - Surgical prevention of arm lymphedema after breast cancer treatment.
20002679 - Clearance after vasectomy with a single semen sample containing < than 100 000 immotile...
7880929 - An open study on the safety and efficacy of fluconazole in the treatment of disseminate...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  40     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1994-02-17     Completed Date:  1994-02-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  296-8     Citation Subset:  IM    
Division of the Nephrology Regional Hospital Taranto, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Administration Schedule
Gastrins / blood*
Middle Aged
Omeprazole / administration & dosage,  therapeutic use*
Peptic Ulcer / drug therapy*,  etiology
Renal Dialysis*
Time Factors
Uremia / complications,  therapy*
Reg. No./Substance:
0/Gastrins; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diffusion kinetics of urea, creatinine and uric acid in blood during hemodialysis. Clinical implicat...
Next Document:  Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients fol...